Lyric Bio, Inc. is leveraging ultra-fast bioprinting technology licensed from Prellis Biologics, Inc that can deliver bioreactors with cell densities that match human tissue for therapeutics production. The technology will drive massive gains in efficiency, and for the first time, allow several donor derived therapies to be manufactured in bioreactors. Lyric Bio is excited to deliver both cost reduction and flexible biomanufacturing to the donor-derived therapeutics market.
“Black Diamond Ventures is a true partner to innovators, supporting technologies that will have a positive generational impact on the world around us, I am proud to be part of the BDV family.”
– Melanie Matheu, PhD, Founder of Prellis Biologics, Inc. and Co-Founder and CSO of Lyric Bio
“Black Diamond Ventures has been an exceptional partner to Lyric Bio, bringing not just capital but also deep strategic insight and operational expertise stemming from their decades of experience.”
– Kayj Shannon, CEO and Co-Founder of Lyric Bio
